Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Reports Stock and Option Awards
SEC Form 4 Filing
Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.
Summary
- Joshua Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals, reported changes in beneficial ownership.
- On April 16, 2024, Cohen acquired 179,850 shares of common stock through a restricted stock unit (RSU) award.
- These RSUs vest in three tranches: 33% on September 30, 2024, 33% on March 31, 2025, and 34% on September 30, 2025, contingent upon continued service.
- Cohen also acquired options to purchase 380,000 shares of common stock at an exercise price of $2.01.
- These options vest 25% on April 16, 2025, and the remaining shares vest monthly over the subsequent 36 months, also contingent upon continued service.
- Following these transactions, Cohen beneficially owns 3,202,852 shares of common stock and options for 380,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive signal.
Positives
- The granting of RSUs and stock options to the Co-CEO aligns his interests with those of the shareholders.
- The vesting schedules for both the RSUs and stock options incentivize continued service and commitment to the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the equity awards.
Industry Context
This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Equity compensation packages for CEOs in the pharmaceutical industry typically include a mix of stock options and restricted stock units.
- Vesting schedules are often tied to performance metrics and/or continued employment, aligning executive compensation with shareholder value.
- Companies like Biogen, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term company performance.
- Employees may see this as a sign of stability and commitment to leadership.
Key Dates
| Date | Description |
|---|---|
| 04/16/2024 | Date of transaction: Grant of RSUs and stock options. |
| 04/16/2024 | Stock options granted. |
| 09/30/2024 | First vesting date for 33% of RSUs. |
| 03/31/2025 | Second vesting date for 33% of RSUs. |
| 04/16/2025 | First vesting date for 25% of stock options. |
| 09/30/2025 | Final vesting date for 34% of RSUs. |
| 04/15/2034 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.